AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01782612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total uni-Hip Replacement
Description: All subjects will undergo standard Total uni-Hip Replacement
Study NCT01885026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment only of alcohol and drug use.
Description: Assessment of alcohol and drug use at baseline and follow-up.
Study NCT04456803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric citrate tablet
Description: 250mg/tablet, manufactured by Sinomune Pharmaceutical
Study NCT04456803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer carbonate tablet
Description: 800 mg/tablet, manufactured by Genzyme Ireland Limited
Study NCT01910649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drisapersen
Description: Subcutaneous and Intravenous
Study NCT04804111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: arm 0
Description: placebo group
Study NCT04804111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arm 1
Description: 3 mg of the URC102 group
Study NCT04804111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arm 2
Description: 6 mg of the URC102 group
Study NCT04804111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arm 3
Description: 9 mg of the URC102 group
Study NCT04804111 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: arm 4
Description: Febuxostat 80 mg
Study NCT03640728 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Alafenamide
Description: Tenofovir alafenamide 25 mg/day orally
Study NCT03640728 — intervention group
Intervention type: DRUG
Intervention: Entecavir
Description: Entecavir 0.5 mg/day orally
Study NCT03640728 — intervention group
Intervention type: DRUG
Intervention: Tenofovir disoproxil fumarate
Description: Tenofovir Disoproxil Fumarate 300 mg/day orally
Study NCT01885026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based treatment for depression or anxiety
Description: Internet-based treatment for primary diagnoses of depression, panic anxiety or social phobia.
Study NCT03862586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Study NCT03862586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT03198728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOV2012-F1
Description: oral preparation of testosterone undecanoate (TU)
Study NCT03198728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AndroGel
Description: topical testosterone gel 1.62%
Study NCT01481428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-facilitated HIV intervention
Description: Individuals assigned to the experimental condition will complete the self-directed CARE HIV intervention during each of their first three sessions. The 20 minute intervention sessions involve several components including a brief risk assessment, review of identified risks, structured skill building videos, and the development of a risk prevention action plan. Because of the adaptive nature of the CARE program, the content of each session will be tailored to address the current risks of the participant. While the main focus of the intervention is on risk, individuals who report being HIV infected will receive a referral to treatment if they are not currently receiving medical care and their session will address, among other things, adherence to HIV care.
Study NCT01481428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Life skills training DVDs that match the duration of the anticipated experimental condition. The DVDs address topics such as positive listening skills, anger management, and stress reduction.
Study NCT00960635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1,25-dihydroxy-vitamin D3 (calcitriol)
Study NCT00960635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: pill without agent
Study NCT03250819 — intervention group
Intervention type: OTHER
Intervention: SNP analysis
Description: The collected blood samples will be used to investigate the occurrence of SNPs (single nucleotide polymorphisms) in both study groups
Study NCT00684463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: 0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.
Study NCT04051944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
Study NCT00675129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavioral therapy for adolescents (DBT-A)
Description: Patients randomised to DBT-A will receive 16 weeks treatment, with one weekly session (60 minutes)of individual therapy, one weekly session of multifamily skills training (120 minutes), and telephone coaching outside therapy sessions.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively.
Study NCT00675129 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Patients randomised to EUC will received standard care (16 weeks) at five participating child and adolescent outpatient clinics from therapists not trained in or practising DBT. According to pilot study data EUC will most likely consist of psychodynamic therapy, various forms of family therapy and supportive therapy.
Study NCT01982669 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Study NCT02393989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior restoration
Description: restorations for caries effected teeth
Study NCT02466906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Description: rhGM-CSF was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. During adjuvant therapy of XELOX, rhGM-CSF was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15) or stopped when ANC>20.0X109/L.
Study NCT02466906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
Study NCT01873599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Journaling
Study NCT01066611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAL-263
Description: CAL-263 10 mg or placebo once daily for 7 days
Study NCT01066611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CAL-263 10 mg or placebo once daily for 7 days
Study NCT00045019 — intervention group
Intervention type: OTHER
Intervention: quality-of-life assessment
Description: QLQ-C30 SAT32
Study NCT03563651 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04549675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Safe Partners Online
Description: Sun Safe Partners Online has 4 individual-focused modules and 4 couple-focused modules focusing on skin cancer prevention education and sun protection.
Study NCT04549675 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic Online Sun Safety Information intervention
Description: 4 links to sent to participants from (1) The Skin Cancer Foundation's Skin Cancer Prevention guidelines, (2) the Centers for Disease Control and Prevention's information on risk factors for skin cancer, (3) the American Academy of Dermatology's information on how to select an appropriate sunscreen, and (4) The Skin Cancer Foundation's information on sun protective clothing. Participants were emailed a link to one of the resources each week for 4 weeks.
Study NCT03869489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal left dorsolateral prefrontal cortex tDCS stimulation
Description: Anodal tDCS will be applied to the left dorsolateral prefrontal cortex of participants
Study NCT03869489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal right dorsolateral prefrontal cortex tDCS stimulation
Description: Anodal tDCS will be applied to the right dorsolateral prefrontal cortex of participants
Study NCT03869489 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS stimulation
Description: Sham tDCS stimulation will be applied
Study NCT03112499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCNL
Description: Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using either balloon (20 atm) or Amplatz serial dilators a 30F access channel is created. Lithotripsy is performed using ultrasound lithotripter and stone fragments are removed by grasping forceps. At the end of the operation a 18F Council type catheter is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Council and JJ catheter are removed,in the absence of complications, the second and tenth postoperative day, respectively.
Study NCT03112499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mini-PCNL
Description: Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using Amplatz serial dilators a 16F access channel is created. Lithotripsy is performed using using 270mm Ho: YAG laser fiber and stone fragments are removed by grasping forceps. At the end of the operation a 10F nephrostomy tube is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Nephrostomy tube and JJ catheter are removed, in the absence of complications, the second and tenth postoperative day, respectively.
Study NCT03112499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS
Description: Under general anesthesia and patient in lithotomy position, a 0.035 hydrophilic safety wire is inserted in the ureter under fluoroscopic guidance. Subsequently 8-10 F dilators are used for dilation of the ureter.Insertion of a second working wire follows above which a 14F ureteral sheath is placed. Lithotripsy with a flexible ureteroscope using 270mm Ho: YAG laser fiber follows.Remaining stone fragments are removed by a 2,2F nitinol basket. At the end of the operation a JJ indwelling ureteral catheter is placed over the safety wire. Discharge is performed in the absence of complications, the first postoperative day while JJ catheter is removed on the 10th postoperative day.
Study NCT03523715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prunes
Description: 12 oz of prunes daily
Study NCT03523715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docusate Sodium
Description: Oral docusate sodium twice daily
Study NCT03523715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docusate Sodium
Description: Oral docusate sodium twice daily
Study NCT04684706 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: intermittent Theta Burst Stimulation
Description: The present study will utilize TMS dosage of iTBS of 18 000 pulses a day for 5 consecutive days.
Study NCT05335785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity lazer therapy
Description: Patients in the laser group will be given hiltherapy (high-intensity laser) with the HIRO 3 device every other day. One session of laser therapy application consists of 3 phases: the beginning, the middle and the ending phase. The initial phases are fast scanning and the ending phase is slow scanning. A total of 2000 J will be applied to the rotatorcuff muscles, the upper part of the trapezius muscle, the deltoid muscle and the pectoralis major muscle, 1000 J in the rapid scan phase and 1000 J in the finishing phase. In the middle phase, 50 J will be applied for the trigger point (hard intramuscular points that cause referred pain) in each muscle and a maximum of 500 J in total. The total dose prescribed for patients in one session will be 2500 J. Each phase will be 15 minutes on average and the session will last for 45 minutes in total. The laser probe will be applied with 90 degrees. During the application, the practitioner and the patient will have protective glasses.
Study NCT03563651 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, urine, and stool
Study NCT03563651 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03994211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamiparib 60 mg
Description: Single dose of 60 mg pamiparib orally on Days 1 and 10
Study NCT03994211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamiparib 20 mg
Description: Single dose of 20 mg pamiparib orally on days 1 and 7
Study NCT03994211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: 200 mg itraconazole once a day al Day 3 to day 8
Study NCT03994211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Description: 600 mg rifampin once a day from days 3 to 11
Study NCT03994211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamiparib
Description: 60 mg pamiparib orally twice a day in 28-day cycles
Study NCT04662775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HERizon Project
Description: 1. Participants were asked to complete 3x30-minute physical activity sessions each week \& record their sessions using a logbook. They were given the choice of different types of home-based virtual exercise. 2. Behaviour change support calls - participants were allocated an Activity Mentor (trainee sport and exercise psychologists, was supervised by a HCPC-registered Psychologist). Participants had seven weekly videocalls. Each call was based on a pre-planned session outline and was goal orientated, participant centred and focused on physical activity. 3. No reply SMS - Participants received 3 standardised text messages each week, aimed at providing physical activity -related facts, encouragement and study information.
Study NCT01179828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 15mg
Description: 15mg single administration p.o.
Study NCT01179828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobazam
Description: 20mg single administration p.o.
Study NCT01179828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: 75mg single administration p.o.
Study NCT01179828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolterodine
Description: 1 mg single administration p.o.
Study NCT05727007 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI in colon cancer
Description: The MRI protocol will include the following imaging series: T1 and T2 in axial and coronal plane before the administration of intravenous contrast, diffuse weight imaging in axial plane and T1 after the administration of intravenous contrast
Study NCT05727007 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT in colon cancer
Description: The CT scan protocol will include the following: per os and intravenous administration of contrast, axial slices of 0.3mm thickness and reconstruction per 1mm, multi-planar reformation and three-dimensional volume rendering
Study NCT02003794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl solution
Description: 0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
Study NCT03066960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency neurotomy
Description: RF neurotomy represents a nerve destructive, coagulating technique affecting the conduction through all nerve fibers.
Study NCT03066960 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Sham treatment represents no coagulation of the nerve and will not affect the nerve conduction.
Study NCT04550520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon with the empirical formula of C153H225N43O49S, and a molecular weight of 3483 g/mol, is a single-chain polypeptide containing 29 amino acid residues. Glucagon is provided in a single dose vial as powder. One container contains 1 mg of glucagon which results in a concentration of 1 mg/ml after dissolution in a volume of 1 ml (Glucagen NovoNordisk (Hypokit)). The currently used standard dose regimen is 1 mg of glucagon in adults. The solution for subcutaneous injection will be prepared by the study personnel according to the attached package leaflet.
Study NCT03203525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT03563651 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03654820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVP-I solution combined with NaF varnish
Description: 4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
Study NCT03654820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SDF solution
Description: Annual application of 38% SDF solution
Study NCT01852500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Osteopathic Manipulative Treatment
Description: Patients from this group received sham osteopathic treatments twice a week for the entire length of stay in the unit.
Study NCT04550520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placebo
Description: As placebo 1 ml sodium chloride (NaCl) 0.9% to inject subcutaneous is used. It has the same optical appearance as glucagon.
Study NCT03316118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Group 1 will receive genicular nerve block using bupivacaine
Study NCT03316118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Group 2 will receive genicular nerve block using normal saline
Study NCT02613494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine
Description: 300 micrograms twice daily, increasing to 300 micrograms three times daily
Study NCT03203525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given via pump
Study NCT03203525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given via pump
Study NCT03203525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given via pump
Study NCT03203525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT03203525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT03203525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy
Description: Use NovoTTF-100L(P) system
Study NCT02613494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: 1 milligram twice daily, increasing to 1 milligram three times daily
Study NCT02613494 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily, increasing to placebo three times daily
Study NCT00908323 — intervention group
Intervention type: BIOLOGICAL
Intervention: JS7 DNA vaccine
Study NCT01745965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Study NCT01745965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Study NCT05335785 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercises
Description: Exercise program including Codman, Range of motion and streightening exercises three times in a week.
Study NCT03397199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib + S-1
Description: Apatinib 250mg/d,q.d.,p.o. A course of treatment need 21days. S-1 40-60mg（40mg bid BSA \<1.4, 60mg bid BSA>1.4），bid,from day1-day 14.
Study NCT00908323 — intervention group
Intervention type: BIOLOGICAL
Intervention: MVA/HIV62 vaccine
Study NCT02450435 — intervention group
Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.
Study NCT00261378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterialchemoembolisation (TACE)
Study NCT02450435 — intervention group
Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.